Abeona Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ABEO Nasdaq 2836 www.abeonatherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Abeona Therapeutics Inc.

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million - Jul 2nd, 2025 5:30 am
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy - Jul 1st, 2025 5:30 am
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jul 1st, 2025 5:15 am
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index - Jun 30th, 2025 5:30 am
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa - Jun 24th, 2025 5:30 am
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference - May 30th, 2025 6:46 am
ABEO: Sells Priority Review Voucher for $155 Million… - May 19th, 2025 7:23 am
Abeona Therapeutics: Q1 Earnings Snapshot - May 15th, 2025 5:38 am
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates - May 15th, 2025 5:30 am
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder - May 14th, 2025 6:07 am
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder - May 14th, 2025 5:30 am
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder - May 14th, 2025 5:30 am
Abeona secures cash runway with $155m priority review voucher sale - May 13th, 2025 5:21 am
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million - May 12th, 2025 5:30 am
Abeona sells speedy drug review voucher for $155M - May 12th, 2025 2:38 am
FDA approves Abeona’s $3.1m cell therapy for rare skin disease - Apr 30th, 2025 5:16 am
ABEO: Zevaskyn™ Approved by FDA; Raising Valuation to $11… - Apr 30th, 2025 4:05 am
Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy - Apr 29th, 2025 1:06 pm
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) - Apr 29th, 2025 4:00 am
ABEO: Countdown to PDUFA Date of April 29, 2025… - Mar 24th, 2025 8:04 am